Citius Pharmaceuticals (NASDAQ:CTXR) Receives Buy Rating from D. Boral Capital

Citius Pharmaceuticals (NASDAQ:CTXR)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $9.00 target price on the stock. D. Boral Capital’s price objective points to a potential upside of 130.18% from the stock’s previous close.

Separately, HC Wainwright reissued a “buy” rating and issued a $100.00 target price on shares of Citius Pharmaceuticals in a research report on Tuesday, November 12th.

Citius Pharmaceuticals Stock Performance

Shares of NASDAQ CTXR opened at $3.91 on Tuesday. The stock’s 50-day simple moving average is $5.12 and its 200-day simple moving average is $11.62. The firm has a market capitalization of $30.21 million, a PE ratio of -0.65 and a beta of 1.30. Citius Pharmaceuticals has a fifty-two week low of $2.44 and a fifty-two week high of $26.75.

Institutional Trading of Citius Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Armistice Capital LLC acquired a new position in Citius Pharmaceuticals during the second quarter worth about $5,928,000. Cubist Systematic Strategies LLC purchased a new stake in Citius Pharmaceuticals in the 2nd quarter valued at approximately $69,000. Point72 DIFC Ltd acquired a new stake in Citius Pharmaceuticals during the 2nd quarter valued at $29,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Citius Pharmaceuticals in the second quarter worth $118,000. Finally, Wealth Advisory Solutions LLC increased its position in Citius Pharmaceuticals by 33.1% during the 3rd quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company’s stock worth $101,000 after purchasing an additional 50,000 shares in the last quarter. Hedge funds and other institutional investors own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.